News

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over 1000 students interested, with over 350 submissions by the closing date. Students have shown interest in all regions across the Commonwealth of Virginia, with specific student interests in bioengineering (180), medical devices (194), and pharmaceuticals (210) respectively.

 

Currently, over 25 employers including; Atelerix Life Sciences Inc. (Charlottesville/Albemarle), ReAlta Life Sciences and LifeNet Health (Coastal VA), Athari Bio Sciences, Inc. and Polaris Genomics (Northern VA), Tympanogen (Richmond), CytoRecovery (Roanoke), and many others across Virginia have registered to host student interns. Employers are encouraged to register as application reviews have just begun and will continue to mid-March to ensure student award letters are presented to the 100 candidates by March 31, 2022. This extraordinary experience is great for the next generation of life science professionals. If you are interested in hosting a student intern, please register here to receive your link to begin reviewing applications.

Any questions you have before registering, please contact VA Bio-Connect Admin at vbcintern@vabio.org for assistance. We look forward to matching you with qualified candidates.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation